Recursion Pharmaceuticals Inc (RXRX) News

RXRX 10Q 11/6

RXRX under $10

RXRX under $10

https://x.com/RecursionPharma/status/1841453309342740925

So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline

WALL @ $7.5 , $7.0

https://www.stockscores.com/charts/charts/?ticker=RXRX

Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX

diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT

RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT

Yes, I've been adding shares of RXRX this week.

LC

RXRX

Looks.like a little dilution, but a good buying opportunity, to add some more.

Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX

I had not seen that merger announcement. Never came across in my broker news feed.

Did you see the possible merger news?

LC

RXRX

Running millions of tests per week, to find promising drug candidates.

What we do not know, is how many candidates have entered clinical trials.

When news pops about RXRX origination of promising cures, this will skyrocket.

Oops, missed this one:

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease

Looks ready to move IMO.

LC

RXRX

Looking for a move into the 9.25-9.50 range within the next few weeks.

RXRX looks ready for another move upward.

Settling back down.

Looks like RXRX is making an upward move.

I like RXRX even better!

LC


GOOD to own, Rxrx

How do you like RXRX at $6.65?

RXRX under $9

Hold this one until they discover a promising drug candidate, then play the spike and repurchase on the subsequent slump. Ofc, if they do start identifying promising drug candidates, then it could just keep going up, after proof of concept is shown.

RXRX
Recursion Pharmaceuticals Inc
7.9485
-0.4015 (-4.81%)
Volume: 2,346,108
Day Range: 7.94 - 8.48
Last Trade Time: 2:15:15 PM EDT

RXRX was bought Friday by Cathie Wood for the.ARKK fund
Based on the chart it’s a buy at $5

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)

https://www.msn.com/en-us/money/markets/hedge-funds-are-loading-up-on-this-nvidia-corp-nvda-partner-stock/ar-BB1njsU8?ocid=BingNewsSerp

https://finviz.com/quote.ashx?t=RXRX&p=d

sutter hill, investor

https://pro.manwardpress.com/p/PARTNERTO99MWLLT2YRDSCBP/NMWL4506/?s1=d0587f1afbc14e9f9b10866ff8e6d8b6&h=true

https://www.insidermonkey.com/blog/7-best-under-the-radar-ai-stocks-hedge-funds-are-buying-1307776/

RXRX
Recursion Pharmaceuticals Inc
8.79
0.21 (2.45%)
Volume: 1,471,309
Day Range: 8.60 - 8.87
Last Trade Time: 12:14:29 PM EDT

9 mos



SEVEN MOS; http://www.stockta.com/


9 mos
[-chart]www.stockscores.com/chart.asp?TickerSymbol=RXRX&TimeRange=275&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=RSI&Indicator2=BBW&Indicator3=AccDist&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]


SEVEN MOS; http://www.stockta.com/
[-chart]www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=RXRX&size=analysis&support=0.00,15,0.00,66,0.00,38,0.00,14,0.00,12,0.00,15,0.00,3,0.00,2,0.00,4,0.00,6,0.00,2&trend=[/chart]

Recursion Pharmaceuticals Inc
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA).
Nvidia Invested $50 million into This AI Drug Discovery Biotech
www.nasdaq.com/articles/nvidia-invested-$50-million-into-this-ai-drug-discovery-biotech
www.nasdaq.com/articles/nvidia-invested-$50-million-into-this-ai-drug-discover…

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

https://www.otcmarkets.com/stock/RXRX/news/story?e&id=2857451

Earnings on Thursday

Was only a matter of time before another company jumped on the bandwagon:

"Dell Technologies and Northwestern Medicine to Advance Patient Care through AI Innovation"

https://www.prnewswire.com/news-releases/dell-technologies-and-northwestern-medicine-to-advance-patient-care-through-ai-innovation-302108735.html

RXRX under $10

Joe of Nanolyze explains RXRX

RXRX 10Q 2/27

In a 100 trilliona biology yes

Looks like 5 dollars is a good buy

RXRX will that awful Cathie Wood keep buying

So the Bayer collaboration just pivoted from Fibrosis to Oncology after three years of effort. The good news is the milestones are bigger than the prior indication. The bad news seems to be that AI won't be able to tackle some of the hardest diseases like fibrosis effectively. I would like to see a broadening of partners, and clearly so does the street. And while we have funding to get through 2024, we need higher stock prices to effectively raise capital under the current ATM filing.

RXRX
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Previous close $5.91 +$0.68 (+13.00%)

Today $6.05 +0.14 (+2.37%) Pre-Market

Volume 11,004

Link back for my notes https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173148805

2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell
By Alex Carchidi – Oct 31, 2023 for The Motley Fool

https://stockcharts.com/h-sc/ui?s=RXRX

KEY POINTS
Recursion is forging key relationships with powerful collaborators.
The young biotech's valuation is also looking a lot better now.
However, its finances are nowhere near breakeven yet.

NASDAQ: RXRX
Recursion Pharmaceuticals
Market Cap
$1B
Today's Change
(13.00%) $0.68
Current Price
$5.91
Price as of November 3, 2023, 4:00 p.m. ET

Pioneering businesses tend to carry big risks, but also the potential for big rewards.
Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (RXRX 13.00%). Though it still hasn't brought a product to market just yet, it's begun to receive some attention already for its innovative approach -- and so now is a good time to consider its merits and risks as a long-term investment.

In particular, there are two main reasons to think about buying Recursion, and one key reason to sell or avoid buying it. Let's start with the big-picture view of why it's worthwhile.

Buy: It'll give you exposure to AI in the healthcare sector
It's probably a good idea to have at least some exposure to the healthcare sector in your portfolio. The same goes for artificial intelligence (AI) stocks, and Recursion Pharmaceuticals fits in both those niches quite nicely. It's seeking to develop an AI platform to help guide drug discovery and selection of therapy candidates; its goals are to lower costs and time spent on the drug development process, and to reduce the risk of expensive late-stage pre-clinical or clinical failures.

With that platform in hand, it plans to identify and test its own leads with the goal of eventually commercializing medicines developed in-house. Right now, it has three rare-disease programs in phase 2 trials as well as a pair of programs in phase 1. Those projects will need a few more years before they're ready for regulatory review.

In the meantime, Recursion is hoping to license its platform to the biopharma industry at large to generate some revenue. It already has buy-in from major pharmaceutical competitors like Bayer AG, with which it's collaborating to find leads for drugs to treat fibrosis. Such a vote of confidence isn't a reason to buy the stock on its own, but it's still a positive indicator for the future.

Buy: It's no longer priced at a huge premium
In July, Recursion inked a deal with Nvidia, the chipmaker and perhaps the most hyped AI stock. Nvidia invested $50 million in Recursion to secure its help in building a cloud-based generative AI service for drug discovery and development. The deal sent the biotech's stock flying overnight to an inflated price-to-sales (P/S) multiple near 60.

Since then, the hype surrounding Nvidia has continued, but Recursion's time in the spotlight has drawn to a close for now. Its shares are priced roughly the same as they were prior to the announcement and with a P/S ratio of about 20. So if you were bullish on the company's future before but were scared off by the prospect of overpaying for hyped-up shares, now's a better time to consider making a move.

Sell: Until its business model is validated, it's burning money
One thing that might encourage current investors to ditch shares of Recursion is that it hasn't proven yet its business model is actually viable. It lacks persuasive evidence for its core claims that its AI-based approach cuts research and development (R&D) expenditures, shortens pre-clinical timelines, and results in fewer late-stage failures. Investors who buy the stock now take on the risk that it won't be able to live up to those goals, which are vital to the company's long-term value.

Furthermore, with a net loss of $77 million in the second quarter, Recursion is nowhere near being profitable on the basis of its collaboration activities and sales of software licenses. Nor is it consistently adding to the top line with either segment; its quarterly revenue fell by more than 19% year over year in Q2, to a relatively paltry sum of $11 million. That means even if it has a few powerful collaborators in its corner, there isn't yet enough social proof to drive new customers to its platform in large numbers.

The company might continue to be unprofitable until shortly after it commercializes its first medicine, assuming that happens. Its $406 million of cash and equivalents should be sufficient to fund it through all of next year, and perhaps the first quarter of 2025. To continue operating after that, it'll need to take out a big loan, issue more shares, sign on another big collaborator, or meet one of the milestones for its existing collaborations.

Recursion will likely be able to find the funding it needs. But if that uncertainty bothers you, it's best to sell this stock, as there'll be even more uncertainty on the way for at least a few more years.

might have bottomed here

what happens after the furu's run it up

Adding some on dips

Next leg up soon